Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Medical Research
Published in: European Journal of Medical Research 1/2023

Open Access 01-12-2023 | Review

French recommendations for the management of glycogen storage disease type III

Authors: Camille Wicker, Aline Cano, Valérie Decostre, Roseline Froissart, François Maillot, Ariane Perry, François Petit, Catherine Voillot, Karim Wahbi, Joëlle Wenz, Pascal Laforêt, Philippe Labrune

Published in: European Journal of Medical Research | Issue 1/2023

Login to get access

Abstract

The aim of the Protocole National De Diagnostic et de Soins/French National Protocol for Diagnosis and Healthcare (PNDS) is to provide advice for health professionals on the optimum care provision and pathway for patients with glycogen storage disease type III (GSD III).The protocol aims at providing tools that make the diagnosis, defining the severity and different damages of the disease by detailing tests and explorations required for monitoring and diagnosis, better understanding the different aspects of the treatment, defining the modalities and organisation of the monitoring. This is a practical tool, to which health care professionals can refer. PNDS cannot, however, predict all specific cases, comorbidities, therapeutic particularities or hospital care protocols, and does not seek to serve as a substitute for the individual responsibility of the physician in front of his/her patient.
Literature
1.
Kishnani PS, Austin SL, Arn P, Bali DS, Boney A, Case LE, et al. Glycogen storage disease type III diagnosis and management guidelines. Genet Med. 2010;12(7):446–63.PubMedCrossRef
2.
3.
Sentner CP, Hoogeveen IJ, Weinstein DA, Santer R, Murphy E, McKiernan PJ, et al. Glycogen storage disease type III: diagnosis, genotype, management, clinical course and outcome. J Inherit Metab Dis. 2016;39(5):697–704.PubMedPubMedCentralCrossRef
4.
Berling E, Laforêt P, Wahbi K, Labrune P, Petit F, Ronzitti G, O’Brien A. Narrative review of glycogen storage disorder type III with a focus on neuromuscular, cardiac and therapeutic aspects. J Inherit metab Dis. 2021;44:521–33.PubMedCrossRef
5.
Michon C-C, Gargiulo M, Hahn-Barma V, Petit F, Nadaj-Pakleza A, Herson A, et al. Cognitive profile of patients with glycogen storage disease type III: a clinical description of seven cases. J Inherit Metab Dis. 2015;38(3):573–80.PubMedCrossRef
6.
Martinez CC, Tonon T, Nalin T, Refosco LF, de Souza CFM, Schwartz IVD. Feeding difficulties and orofacial myofunctional disorder in patients with hepatic glycogen storage diseases. JIMD Rep. 2019;45:21–7.PubMedCrossRef
7.
Bao Y, Dawson TL, Chen YT. Human glycogen debranching enzyme gene (AGL): complete structural organization and characterization of the 5’ flanking region. Genomics. 1996;38(2):155–65.PubMedCrossRef
8.
Shen JJ, Chen YT. Molecular characterization of glycogen storage disease type III. Curr Mol Med. 2002;2(2):167–75.PubMedCrossRef
9.
Maire I, Mathieu M. Possible prenatal diagnosis of type III glycogenosis. J Inherit Metab Dis. 1986;9(1):89–91.PubMedCrossRef
10.
Maire I, Baussan C, Moatti N, Mathieu M, Lemonnier A. Biochemical diagnosis of hepatic glycogen storage diseases: 20 years French experience. Clin Biochem. 1991;24(2):169–78.PubMedCrossRef
11.
Santer R, Kinner M, Steuerwald U, Kjaergaard S, Skovby F, Simonsen H, et al. Molecular genetic basis and prevalence of glycogen storage disease type IIIA in the Faroe Islands. Eur J Hum Genet EJHG. 2001;9(5):388–91.PubMedCrossRef
12.
Rousseau-Nepton I, Okubo M, Grabs R, FORGE Canada Consortium, Mitchell J, Polychronakos C, et al. A founder AGL mutation causing glycogen storage disease type IIIa in Inuit identified through whole-exome sequencing: a case series. CMAJ Can Med Assoc J J Assoc Medicale Can. 2015;187(2):68–73.CrossRef
13.
Parvari R, Moses S, Shen J, Hershkovitz E, Lerner A, Chen YT. A single-base deletion in the 3’-coding region of glycogen-debranching enzyme is prevalent in glycogen storage disease type IIIA in a population of North African Jewish patients. Eur J Hum Genet. 1997;5(5):266–70.PubMedCrossRef
14.
Krahn M, Biancalana V, Cerino M, Perrin A, Michel-Calemard L, Nectoux J, et al. A national French consensus on gene lists for the diagnosis of myopathies using next-generation sequencing. Eur J Hum Genet. 2019;27(3):349–52.PubMedCrossRef
15.
Goldstein JL, Austin SL, Boyette K, Kanaly A, Veerapandiyan A, Rehder C, et al. Molecular analysis of the AGL gene: identification of 25 novel mutations and evidence of genetic heterogeneity in patients with glycogen storage disease type III. Genet Med Off J Am Coll Med Genet. 2010;12(7):424–30.
16.
Hobson-Webb LD, Austin SL, Bali DS, Kishnani PS. The electrodiagnostic characteristics of glycogen storage disease type III. Genet Med Off J Am Coll Med Genet. 2010;12(7):440–5.
17.
Carvalho JS, Matthews EE, Leonard JV, Deanfield J. Cardiomyopathy of glycogen storage disease type III. Heart Vessels. 1993;8(3):155–9.PubMedCrossRef
18.
Coleman RA, Winter HS, Wolf B, Gilchrist JM, Chen YT. Glycogen storage disease type III (glycogen debranching enzyme deficiency): correlation of biochemical defects with myopathy and cardiomyopathy. Ann Intern Med. 1992;116(11):896–900.PubMedCrossRef
19.
Moses SW, Wanderman KL, Myroz A, Frydman M. Cardiac involvement in glycogen storage disease type III. Eur J Pediatr. 1989;148(8):764–6.PubMedCrossRef
20.
Vertilus SM, Austin SL, Foster KS, Boyette KE, Bali DS, Li JS, et al. Echocardiographic manifestations of glycogen storage disease III: increase in wall thickness and left ventricular mass over time. Genet Med Off J Am Coll Med Genet. 2010;12(7):413–23.
21.
Mogahed EA, Girgis MY, Sobhy R, Elhabashy H, Abdelaziz OM, El-Karaksy H. Skeletal and cardiac muscle involvement in children with glycogen storage disease type III. Eur J Pediatr. 2015;174(11):1545–8.PubMedCrossRef
22.
Olson LJ, Reeder GS, Noller KL, Edwards WD, Howell RR, Michels VV. Cardiac involvement in glycogen storage disease III: morphologic and biochemical characterization with endomyocardial biopsy. Am J Cardiol. 1984;53(7):980–1.PubMedCrossRef
23.
Salemi VMC, Demarchi LMMF, Cabeda EV, Wagenführ J, Tanaka AC. Type III glycogen storage disease mimicking hypertrophic cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2012;13(2):197.PubMedCrossRef
24.
Akazawa H, Kuroda T, Kim S, Mito H, Kojo T, Shimada K. Specific heart muscle disease associated with glycogen storage disease type III: clinical similarity to the dilated phase of hypertrophic cardiomyopathy. Eur Heart J. 1997;18(3):532–3.PubMedCrossRef
25.
Shen J, Bao Y, Chen YT. A nonsense mutation due to a single base insertion in the 3’-coding region of glycogen debranching enzyme gene associated with a severe phenotype in a patient with glycogen storage disease type IIIa. Hum Mutat. 1997;9(1):37–40.PubMedCrossRef
26.
Labrune P, Huguet P, Odievre M. Cardiomyopathy in glycogen-storage disease type III: clinical and echographic study of 18 patients. Pediatr Cardiol. 1991;12(3):161–3.PubMedCrossRef
27.
Preisler N, Haller RG, Vissing J. Exercise in muscle glycogen storage diseases. J Inherit Metab Dis. 2015;38(3):551–63.PubMedCrossRef
28.
Preisler N, Laforêt P, Madsen KL, Prahm KP, Hedermann G, Vissing CR, et al. Skeletal muscle metabolism is impaired during exercise in glycogen storage disease type III. Neurology. 2015;84(17):1767–71.PubMedCrossRef
29.
Preisler N, Pradel A, Husu E, Madsen KL, Becquemin M-H, Mollet A, et al. Exercise intolerance in glycogen storage disease type III: weakness or energy deficiency? Mol Genet Metab. 2013;109(1):14–20.PubMedCrossRef
30.
Brooke MH, Griggs RC, Mendell JR, Fenichel GM, Shumate JB, Pellegrino RJ. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve. 1981;4(3):186–97.PubMedCrossRef
31.
Decostre V, Laforêt P, De Antonio M, Kachetel K, Canal A, Ollivier G, et al. Long term longitudinal study of muscle function in patients with glycogen storage disease type IIIa. Mol Genet Metab. 2017;122(3):108–16.PubMedCrossRef
32.
Decostre V, Laforêt P, Nadaj-Pakleza A, De Antonio M, Leveugle S, Ollivier G, et al. Cross-sectional retrospective study of muscle function in patients with glycogen storage disease type III. Neuromuscul Disord. 2016;26(9):584–92.PubMedCrossRef
33.
ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111–7.CrossRef
34.
Erratum. ATS statement: guidelines for the six-minute-walk test. Am J Repir Crit Care Med. 2002;166:1185.
35.
Tiffin J, Asher EJ. The Purdue pegboard; norms and studies of reliability and validity. J Appl Psychol. 1948;32(3):234–47.PubMedCrossRef
36.
Wary C, Nadaj-Pakleza A, Laforêt P, Claeys KG, Carlier R, Monnet A, et al. Investigating glycogenosis type III patients with multi-parametric functional NMR imaging and spectroscopy. Neuromuscul Disord NMD. 2010;20(8):548–58.PubMedCrossRef
37.
Tobaly D, Laforêt P, Perry A, Habes D, Labrune P, Decostre V, et al. Whole-body muscle magnetic resonance imaging in glycogen-storage disease type III. Muscle Nerve. 2019;60(1):72–9.PubMed
38.
Ben Chehida A, Ben Messaoud S, Ben Abdelaziz R, Ben Ali N, Boudabous H, Ben Abdelaziz I, et al. Neuromuscular involvement in glycogen storage disease type III in fifty Tunisian patients: phenotype and natural history in young patients. Neuropediatrics. 2019;50(1):22–30.PubMedCrossRef
39.
DiMauro S, Hartwig GB, Hays A, Eastwood AB, Franco R, Olarte M, et al. Debrancher deficiency: neuromuscular disorder in 5 adults. Ann Neurol. 1979;5(5):422–36.PubMedCrossRef
40.
Moses SW, Gadoth N, Bashan N, Ben-David E, Slonim A, Wanderman KL. Neuromuscular involvement in glycogen storage disease type III. Acta Paediatr Scand. 1986;75(2):289–96.PubMedCrossRef
41.
Cornelio F, Bresolin N, Singer PA, DiMauro S, Rowland LP. Clinical varieties of neuromuscular disease in debrancher deficiency. Arch Neurol. 1984;41(10):1027–32.PubMedCrossRef
42.
Herlin B, Laforět P, Labrune P, Fournier E, Stojkovic T. Peripheral neuropathy in glycogen storage disease type III: Fact or myth? Muscle Nerve. 2016;53(2):310–2.PubMedCrossRef
43.
Laforêt P, Inoue M, Goillot E, Lefeuvre C, Cagin U, Streichenberger N, et al. Deep morphological analysis of muscle biopsies from type III glycogenesis (GSDIII), debranching enzyme deficiency, revealed stereotyped vacuolar myopathy and autophagy impairment. Acta Neuropathol Commun. 2019;7(1):167.PubMedPubMedCentralCrossRef
44.
Ugawa Y, Inoue K, Takemura T, Iwamasa T. Accumulation of glycogen in sural nerve axons in adult-onset type III glycogenosis. Ann Neurol. 1986;19(3):294–7.PubMedCrossRef
45.
Powell HC, Haas R, Hall CL, Wolff JA, Nyhan W, Brown BI. Peripheral nerve in type III glycogenosis: selective involvement of unmyelinated fiber Schwann cells. Muscle Nerve. 1985;8(8):667–71.PubMedCrossRef
46.
Haagsma EB, Smit GP, Niezen-Koning KE, Gouw AS, Meerman L, Slooff MJ. Type IIIb glycogen storage disease associated with end-stage cirrhosis and hepatocellular carcinoma. The liver transplant group. Hepatol Baltim Md. 1997;25(3):537–40.CrossRef
47.
Demo E, Frush D, Gottfried M, Koepke J, Boney A, Bali D, et al. Glycogen storage disease type III-hepatocellular carcinoma a long-term complication? J Hepatol. 2007;46(3):492–8.PubMedCrossRef
48.
Hijazi G, Paschall A, Young SP, Smith B, Case LE, Boggs T, Amarasekara S, Austin SL, Surekha S, El-Gharbawy A, Deak KL, Muir AJ, Kishnani PS. A retrospective longitudinal study and comprehensive review of adults patients with glycogen storage disease type III. Mol Genet Metab Rep. 2021;29:100821.PubMedPubMedCentralCrossRef
49.
Lee PJ, Patel A, Hindmarsh PC, Mowat AP, Leonard JV. The prevalence of polycystic ovaries in the hepatic glycogen storage diseases: its association with hyperinsulinism. Clin Endocrinol (Oxf). 1995;42(6):601–6.PubMedCrossRef
50.
Quackenbush D, Devito J, Garibaldi L, Buryk M. Late presentation of glycogen storage disease types Ia and III in children with short stature and hepatomegaly. J Pediatr Endocrinol Metab JPEM. 2018;31(4):473–8.PubMedCrossRef
51.
Ismail H. Glycogen storage disease type III presenting with secondary diabetes and managed with insulin: a case report. Cases J. 2009;17(2):6891.CrossRef
52.
Melis D, Rossi A, Pivonello R, Del Puente A, Pivonello C, Cangemi G, et al. Reduced bone mineral density in glycogen storage disease type III: evidence for a possible connection between metabolic imbalance and bone homeostasis. Bone. 2016;86:79–85.PubMedCrossRef
53.
Ben Chehida A, Ben Messaoud S, Ben Abdelaziz R, Mansouri H, Boudabous H, Hakim K, et al. A lower energetic, protein and uncooked cornstarch intake is associated with a more severe outcome in glycogen storage disease type III: an observational study of 50 patients. J Pediatr Endocrinol Metab. 2018;31(9):979–86.PubMedCrossRef
54.
Derks TGJ, Smit GPA. Dietary management in glycogen storage disease type III: what is the evidence? J Inherit Metab Dis. 2015;38(3):545–50.PubMedCrossRef
55.
Bhattacharya K. Investigation and management of the hepatic glycogen storage diseases. Transl Pediatr. 2015;4(3):240–8.PubMedPubMedCentral
56.
Francini-Pesenti F, Tresso S, Vitturi N. Modified Atkins ketogenic diet improves heart and skeletal muscle function in glycogen storage disease type III. Acta Myol Myopathies Cardiomyopathies Off J Mediterr Soc Myol. 2019;38(1):17–20.
57.
Bhattacharya K, Orton RC, Qi X, Mundy H, Morley DW, Champion MP, et al. A novel starch for the treatment of glycogen storage diseases. J Inherit Metab Dis. 2007;30(3):350–7.PubMedCrossRef
58.
Bhattacharya K, Mundy H, Lilburn MF, Champion MP, Morley DW, Maillot F. A pilot longitudinal study of the use of waxy maize heat modified starch in the treatment of adults with glycogen storage disease type I: a randomized double-blind cross-over study. Orphanet J Rare Dis. 2015;10:18.PubMedPubMedCentralCrossRef
59.
Mönch E, Moses S. Inherited disorders of carbohydrate metabolism : glycogen storage diseases and deficiencies of monosaccharide metabolism. UNI-MED Science. 2014;192.
60.
61.
Rossi A, Hoogeveen IJ, Bastek V, de Boer F, Montanari C, Meyer U, et al. Dietary lipids in glycogen storage disease type III: a systematic literature study, case studies, and future recommendations. J Inherit Metab Dis. 2020;43:770–7.PubMedPubMedCentralCrossRef
62.
Hoogeveen IJ, de Boer F, Boostra WF, van der Schaaf C, Steuerwald U, Sibeijn-Kuiper A, et al. Effects of acute nutritional ketosis during exercise in adults with glycogen storage disease type III are phenotype-specific: an investigator-initiated, randomized, crossover study. J Inherit Metab Dis. 2021;44:226–39.PubMedCrossRef
63.
Brambilla A, Mannarino S, Pretese R, Gasperini S, Galimberti C, Parini R. Improvement of cardiomyopathy after high-fat diet in two siblings with glycogen storage disease type III. JIMD Rep. 2014;17:91–5.PubMedPubMedCentralCrossRef
64.
Dagli AI, Zori RT, McCune H, Ivsic T, Maisenbacher MK, Weinstein DA. Reversal of glycogen storage disease type IIIa-related cardiomyopathy with modification of diet. J Inherit Metab Dis. 2009;32(Suppl 1):S103-106.PubMedCrossRef
65.
Sentner CP, Caliskan K, Vletter WB, Smit GPA. Heart failure due to severe hypertrophic cardiomyopathy reversed by low calorie, high protein dietary adjustments in a glycogen storage disease type iiia patient. JIMD Rep. 2012;5:13–6.PubMedCrossRef
66.
Valayannopoulos V, Bajolle F, Arnoux J-B, Dubois S, Sannier N, Baussan C, et al. Successful treatment of severe cardiomyopathy in glycogen storage disease type III With D, L-3-hydroxybutyrate, ketogenic and high-protein diet. Pediatr Res. 2011;70(6):638–41.PubMedCrossRef
67.
Herbert M, Pendyal S, Rairikar M, Halaby C, Benjamin RW, Kishnani PS. Role of continuous glucose monitoring in the management of glycogen storage disorders. J Inherit Metab Dis. 2018;41(6):917–27.PubMedCrossRef
68.
Iyer SG, Chen C-L, Wang C-C, Wang S-H, Concejero AM, Liu Y-W, et al. Long-term results of living donor liver transplantation for glycogen storage disorders in children. Liver Transplant. 2007;13(6):848–52.CrossRef
69.
Davis MK, Weinstein DA. Liver transplantation in children with glycogen storage disease: controversies and evaluation of the risk/benefit of this procedure. Pediatr Transplant. 2008;12(2):137–45.PubMedCrossRef
70.
Chabrol B, Jacquin P, Francois L, Broué P, Dobbelaere D, Douillard C, et al. Transition from pediatric to adult care in adolescents with hereditary metabolic diseases: Specific guidelines from the French network for rare inherited metabolic diseases (G2M). Arch Pediatr. 2018;25:344–9.CrossRef
71.
Vidal P, Pagliarani S, Colella P, Costa Verdera H, Jauze L, Gjorgjieva M, et al. Rescue of GSDIII phenotype with gene transfer requires liver- and muscle-targeted GDE expression. Mol Ther. 2018;26(3):890–901.PubMedCrossRef
72.
Ramachandran R, Wedatilake Y, Coats C, Walker F, Elliott P, Lee PJ, et al. Pregnancy and its management in women with GSD type III—a single centre experience. J Inherit Metab Dis. 2012;35(2):245–51.PubMedCrossRef
Metadata
Title
French recommendations for the management of glycogen storage disease type III
Authors
Camille Wicker
Aline Cano
Valérie Decostre
Roseline Froissart
François Maillot
Ariane Perry
François Petit
Catherine Voillot
Karim Wahbi
Joëlle Wenz
Pascal Laforêt
Philippe Labrune
Publication date
01-12-2023
Publisher
BioMed Central
Published in
European Journal of Medical Research / Issue 1/2023
Electronic ISSN: 2047-783X
DOI
https://doi.org/10.1186/s40001-023-01212-5

Other articles of this Issue 1/2023

European Journal of Medical Research 1/2023 Go to the issue

Research

The epidemiology of Helicobacter pylori resistance in a university affiliated hospital: a comparison between two time periods—a cross-sectional design

Research

The characteristics of extrachromosomal circular DNA in patients with end-stage renal disease

Research

Therapeutic and adverse effects of adrenaline on patients who suffer out-of-hospital cardiac arrest: a systematic review and meta-analysis

Research

Development and validation a model for predicting overall survival of bladder cancer with lung metastasis: a population-based study

Research

Differentiation between cerebral alveolar echinococcosis and brain metastases with radiomics combined machine learning approach

Research

Integrated investigation of the clinical implications and targeted landscape for RNA methylation modifications in hepatocellular carcinoma